Aspira Women’s Health to Present at the 2023 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Conference

AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it would present at the upcoming 2023 American College of Obstetricians and Gynecologists (“ACOG”) Annual Clinical & Scientific Conference being held in Baltimore, MD on May 19-21, 2023.

Dr. Leo Twiggs, Director of Medical Affairs and Dr. Ryan Phan, Chief Scientific Officer will present Aspira Women’s Health Ovarian Cancer Risk Assessment Portfolio for Women with Adnexal Masses on Saturday, May 20^th at 6:15 pm.

“Dr. Twiggs and I are honored to present our OvaSuite^SM products to physicians who are dedicated to women and women’s health,” said Dr. Ryan Phan, Chief Scientific Officer of Aspira. “I am especially looking forward to talking about our latest test, OvaWatch^SM, which addresses a long-standing unmet need to provide data-driven insight for the initial clinical assessment of pelvic masses.”

The ACOG Annual Clinical and Scientific Meeting (ACSM) has long been a gathering of the leading women’s health care experts and is a must-attend industry event for those committed to providing exceptional obstetric and gynecologic care. As the largest and most respected medical meeting for women’s health, ACSM provides attendees with cutting-edge research, clinical best practices and collaborative solutions to the challenges faced by ob-gyns and affiliate health care providers.

Aspira Women’s Health is also hosting an Investor Day on OvaWatch℠ and EndoCheck Market Opportunities on May 23, 2023, featuring two key opinion leaders.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM. OvaWatch^SM is a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus combines our FDA-cleared products, Ova1 and Overa, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.